Pichia pastoris as One of the Best Choice for Expression of Biopharmaceutical Proteins

AUTHORS

Masoud Keikha ORCID 1 , *

AUTHORS INFORMATION

1 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

How to Cite: Keikha M. Pichia pastoris as One of the Best Choice for Expression of Biopharmaceutical Proteins, Int J Health Life Sci. Online ahead of Print ; 5(1):e87190. doi: 10.5812/ijhls.87190.

ARTICLE INFORMATION

International Journal of Health and Life Sciences: 5 (1); e87190
Published Online: January 13, 2019
Article Type: Letter
Received: December 8, 2018
Revised: January 6, 2019
Accepted: January 8, 2019
Crossmark

Crossmark

CHEKING

READ FULL TEXT

Dear Editor,

Bioproducts such as vaccines, antibodies, antiviral peptides like interferon-γ, insulin, growth hormone (GH) and erythropoietin are models of biopharmaceuticals which are applied for therapeutic goals in modern medicine; In 2014, the global market has been estimated 44 billion $ for recombinant biopharmaceutical proteins which is predicted that extended to 70 billion $ in 2010 (1, 2). In the other hand, during last decades, the mammalian cell lines and Escherichia coli expression systems are available options for expressing and production of recombinant proteins; but there are serious problems such as slow growth rate replication, requiring to expensive synthetic media and susceptibility to viral contamination in mammalian cell lines, while bacterial expressing systems are associated with phage contamination, need to purification of bacterial toxins and limited in post modification translation (PMT) process (1-3). Beside these problems, increasing globally demands of biopharmaceutical proteins have been major reasons for developing genetic-manipulation process to introduction of new efficient expressing system which high-yield economical (2, 4).

Pichia pastoris (currently re-classified as Komagataella pastoris) is methylotrophic yeast that known as one of the great expressing machine in biotechnology works which is able to produce about more than 500 high titers heterologous proteins since 1750s until now (2, 5). This micro-organism was first introduced by Phillips Petroleum as animal food-additive based on a high cell density fermentation process employing methanol as sole carbon source. This fermentative-yeast can be easily manipulated that successfully secret numerous heterologous proteins with high titers, while secreting low quantities of endogenous proteins (5).

P. pastoris expression systems are usually based on the methanol-induced alcohol oxidase (AOX1) promoter which control expression of foreign genes by oxidation of methanol to formaldehyde and hydrogen proxide. P. pastoris strains was classified in three different phenotypes according to utilizing methanol. (1) Mut+ that have functional form of the both AOX genes (AOX1-2); this strains require large amounts of methanol and dependency of type Mut+ to high concentration of methanol lead to serious problem to control of expressing level of foreign genes. (2) Muts strains with deletion in AOX1 gene (AOX1 expression constitute almost 90% of functional proteins in P. pastoris) which are low growth rate. (3) Mut- strains that both AOX1 and AOX2 were deleted in this strains that cannot grow on methanol (2, 3). Moreover, methanol is toxic for human, flammable and hazardous substance; therefore, another promoter are introduced such as GAP, FLD1, PEX8, and YPT7 which are not required to methanol. for example, GAP (glyceraldehyde 3-phosphate) promoter is continuous promoter that expressed on glucose or glycerol contained growth media; according to literatures, there are opposed opinion in efficacy of GAP promoter compared with pAOX1-2 (2, 3, 6).

Pichia pastoris is an expert expressing system with more popularity due to (1) rapid growth rate on simple media, (2) expressing low quantities of endogenous protein, (3) prevention of viral or bacterial toxins contamination, (4) easily genetic engineering, (5) post modification translation consisting glycosylation, folding, disulfide bond, acylation, methylation, proteolytic and targeting process, (6) simple promoter inducing and (7) recombinant protein can easily extracted without harvesting of any yeast cells (2, 3) Saccharomyces cerevisiae is classic eukaryotic expressing system and more famous than P. pastoris; glycosylation patterns of these yeasts are different. Whoever, mannosylation and terminal a-1,3-mannose linkages are created by S. cerevisiae, this process cause of poor serum half-life or even allergenic and inducing immune-response against biopharmaceutical proteins. Also research approved that expression of secretory proteins in P. pastoris is better than S. cerevisiae (7, 8).

In summary, P. pastoris is methylotrophic yeast which has exclusive features (e.g. rapid growth rate, simple requirement, controllable promoter and post modification translation process) to developed it as the best choice of eukaryotic expressing system; Review of the literatures show that P. pastoris is proper host for various industrial enzymes or biopharmaceutical product with efficient economically cost.

Footnotes

References

  • 1. Vogl T, Hartner FS, Glieder A. New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris. Curr Opin Biotechnol. 2013;24(6):1094-101. doi: 10.1016/j.copbio.2013.02.024. [PubMed: 23522654]. [PubMed Central: PMC3841573].
  • 2. Potvin G, Ahmad A, Zhang Z. Bioprocess engineering aspects of heterologous protein production in Pichia pastoris: A review. Biochem Eng J. 2012;64:91-105. doi: 10.1016/j.bej.2010.07.017.
  • 3. Li P, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, Duzgunes N, et al. Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol. 2007;142(2):105-24. [PubMed: 18025573].
  • 4. Goodman M. Market watch: Sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov. 2009;8(11):837. doi: 10.1038/nrd3040. [PubMed: 19876035].
  • 5. Cregg JM, Cereghino JL, Shi J, Higgins DR. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000;16(1):23-52. doi: 10.1385/MB:16:1:23. [PubMed: 11098467].
  • 6. Prielhofer R, Cartwright SP, Graf AB, Valli M, Bill RM, Mattanovich D, et al. Pichia pastoris regulates its gene-specific response to different carbon sources at the transcriptional, rather than the translational, level. BMC Genomics. 2015;16:167. doi: 10.1186/s12864-015-1393-8. [PubMed: 25887254]. [PubMed Central: PMC4408588].
  • 7. Darby RA, Cartwright SP, Dilworth MV, Bill RM. Which yeast species shall I choose? Saccharomyces cerevisiae versus Pichia pastoris (review). Methods Mol Biol. 2012;866:11-23. doi: 10.1007/978-1-61779-770-5_2. [PubMed: 22454110].
  • 8. Kamal S, Khan SU, Muhammad N, Shoaib M, Omar M, Pascal K, et al. Insights on heterologous expression of fungal cellulases in Pichia pastoris. Biochem Mol Biol. 2018;3(1):15. doi: 10.11648/j.bmb.20180301.13.
  • COMMENTS

    LEAVE A COMMENT HERE: